# Prostamax

> Synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.

- Also known as: Lys-Glu-Asp-Pro, KEDP tetrapeptide
- Class: Reproductive, Bioregulators
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/prostamax

## Overview

Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro) in the Khavinson short-peptide bioregulator series, directed at prostate tissue. It was conceived as the defined single-sequence successor to older bovine prostate extracts (such as Prostatilen), studied for prostate inflammation and age-related remodeling.

Prostamax (Lys-Glu-Asp-Pro) is the prostate-directed member of the defined short-peptide bioregulator family. Where the earlier generation used bovine prostate extracts (Prostatilen, Vitaprost), Prostamax is the synthetic, single-sequence peptide meant to reproduce that tissue-selective effect in a defined molecule.

Reported research — largely Khavinson-school animal and cell-culture work — describes reduced prostate inflammation and slowed pathological remodeling in rat prostatitis models. There are no Western randomized trials of the synthetic peptide and no independent replication outside the originating institute, and it is not FDA-approved.

## Mechanism

Proposed gene-regulatory modulation of prostate gene expression.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C20H33N5O9 |
| Molecular weight | 487.5 Da |

## Sequence

```
KEDP
```

## Research areas

Studied in: Prostate health, Aging biology, Peptide bioregulators.

Guides on this site:

- [Longevity & Aging](https://americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience.
- [Peptide Bioregulators](https://americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Prostate focus — studied for reduced prostate inflammation and slowed pathological remodeling in preclinical prostatitis models.
- Successor to extracts — the defined-sequence synthetic counterpart to older bovine prostate extracts (Prostatilen, Vitaprost).
- Class mechanism — proposed short peptide–DNA interaction driving tissue-selective gene expression.
- Evidence quality — single-tradition and largely preclinical; no independent replication. Not FDA-approved.

## Storage, handling & synthesis

**Synthesis.** Prostamax (Lys-Glu-Asp-Pro) is a tetrapeptide made by routine solid-phase synthesis; the proline residue is a standard building block, so assembly is straightforward and quality hinges on deletion-sequence and counterion control.

## FAQs

### What is Prostamax?

Prostamax is a synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator in the Khavinson short-peptide series.

### How does it relate to older prostate extracts?

It is the defined single-sequence synthetic successor to bovine prostate extracts like Prostatilen and Vitaprost, meant to reproduce their tissue-selective effect in a defined molecule.

### How strong is the evidence?

It is concentrated in one research tradition and largely preclinical, with no independent replication. This page is a research and educational reference.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/prostamax
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.